RESUMO
PURPOSE: Information about the impact on the adult health care system is limited for complex rare pediatric diseases, despite their increasing collective prevalence that has paralleled advances in clinical care of children. Within a population-based health care context, we examined costs and multimorbidity in adults with an exemplar of contemporary genetic diagnostics. METHODS: We estimated direct health care costs over an 18-year period for adults with molecularly confirmed 22q11.2 microdeletion (cases) and matched controls (total 60,459 person-years of data) by linking the case cohort to health administrative data for the Ontario population (â¼15 million people). We used linear regression to compare the relative ratio (RR) of costs and to identify baseline predictors of higher costs. RESULTS: Total adult (age ≥ 18) health care costs were significantly higher for cases compared with population-based (RR 8.5, 95% CI 6.5-11.1) controls, and involved all health care sectors. At study end, when median age was <30 years, case costs were comparable to population-based individuals aged 72 years, likelihood of being within the top 1st percentile of health care costs for the entire (any age) population was significantly greater for cases than controls (odds ratio [OR], for adults 17.90, 95% CI 7.43-43.14), and just 8 (2.19%) cases had a multimorbidity score of zero (vs 1483 (40.63%) controls). The 22q11.2 microdeletion was a significant predictor of higher overall health care costs after adjustment for baseline variables (RR 6.9, 95% CI 4.6-10.5). CONCLUSION: The findings support the possible extension of integrative models of complex care used in pediatrics to adult medicine and the potential value of genetic diagnostics in adult clinical medicine.
Assuntos
Custos de Cuidados de Saúde , Humanos , Masculino , Feminino , Adulto , Adulto Jovem , Ontário/epidemiologia , Idoso , Adolescente , Pessoa de Meia-Idade , Síndrome de DiGeorge/genética , Síndrome de DiGeorge/economia , Síndrome de DiGeorge/epidemiologia , Envelhecimento/genética , Estudos de Casos e Controles , Deleção Cromossômica , Cromossomos Humanos Par 22/genéticaRESUMO
RATIONALE: A common strategy to reduce COPD readmissions is to encourage patient follow-up with a physician within 1 to 2 weeks of discharge, yet evidence confirming its benefit is lacking. We used a new study design called target randomized trial emulation to determine the impact of follow-up visit timing on patient outcomes. METHODS: All Ontario residents aged 35 or older discharged from a COPD hospitalization were identified using health administrative data and randomly assigned to those who received and did not receive physician visit follow-up by within seven days. They were followed to all-cause emergency department visits, readmissions or death. Targeted randomized trial emulation was used to adjust for differences between the groups. COPD emergency department visits, readmissions or death was also considered. RESULTS: There were 94,034 patients hospitalized with COPD, of whom 73.5% had a physician visit within 30 days of discharge. Adjusted hazard ratio for all-cause readmission, emergency department visits or death for people with a visit within seven days post discharge was 1.03 (95% Confidence Interval [CI]: 1.01-1.05) and remained around 1 for subsequent days; adjusted hazard ratio for the composite COPD events was 0.97 (95% CI 0.95-1.00) and remained significantly lower than 1 for subsequent days. CONCLUSION: While a physician visit after discharge was found to reduce COPD events, a specific time period when a physician visit was most beneficial was not found. This suggests that follow-up visits should not occur at a predetermined time but be based on factors such as anticipated medical need.
Assuntos
Serviço Hospitalar de Emergência , Alta do Paciente , Readmissão do Paciente , Doença Pulmonar Obstrutiva Crônica , Humanos , Doença Pulmonar Obstrutiva Crônica/terapia , Doença Pulmonar Obstrutiva Crônica/epidemiologia , Alta do Paciente/estatística & dados numéricos , Masculino , Feminino , Idoso , Pessoa de Meia-Idade , Readmissão do Paciente/estatística & dados numéricos , Serviço Hospitalar de Emergência/estatística & dados numéricos , Fatores de Tempo , Idoso de 80 Anos ou mais , Ontário/epidemiologia , Seguimentos , Adulto , Hospitalização/estatística & dados numéricosRESUMO
Ontario has both a health system and a research system that are increasingly putting patients and rapid learning and improvement at their centre. For the health system, a recent notable example of such efforts was the Patients First Act 2016 which, among other things, mandated the creation of Patient and Family Advisory Councils at multiple levels in the health system,(4) the formalization of LHIN sub-regions as the focal point for local improvements to the patient experience, and the preparation of annual Quality Improvement Plans by many health organizations. For the research system, a notable example is the efforts by the Ministry of Health and Long-Term Care (MoHLTC) and the Ontario SPOR SUPPORT Unit (OSSU) to support the conduct and use of patient-oriented research.